Yumanity Therapeutics, Inc. (YMTX)
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding.
It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases.
Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial.
The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.
|IPO Date||Feb 11, 2016|
80 Guest St Fl 5
Boston, Massachusetts 02135-2071
|Phone||617 409 5300|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Richard Peters M.D., Ph.D.||Chief Executive Officer, President, Treasurer, Secretary and Director|
|Dr. Vikram Khurana M.D., Ph.D.||Scientific Co-Founder and Senior Advisor of Discovery Biology|
|Chee Yeun Chung Ph.D.||Scientific Co-Founder and Associate Director of Discovery Biology|
|Marie Epstein CPA||Vice President of Finance|
|Michael D. Wyzga||Senior Vice President and Chief Financial Officer|
|Devin Whittemore Smith||Senior Vice President and General Counsel|
|Ellen K. Forest||Chief Human Resources Officer|
|Paulash Mohsen||Senior Vice President and Chief Business Officer|
|Dr. Ajay Verma M.D., Ph.D.||Executive Vice President and Head of Research & Development|
Latest SEC Filings
|Nov 19, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Nov 15, 2021||4||Statement of changes in beneficial ownership of securities|
|Nov 15, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 15, 2021||8-K||Current report|
|Nov 10, 2021||SC 13G/A||Statement of acquisition of beneficial ownership by individuals|
|Nov 10, 2021||8-K||Current report|
|Aug 17, 2021||4||Statement of changes in beneficial ownership of securities|
|Aug 17, 2021||3||Initial statement of beneficial ownership of securities|
|Aug 16, 2021||8-K||Current report|
|Aug 12, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|View All SEC Filings|